The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...

NEW ORLEANS -- Most patients undergoing knee replacement procedures also have joint pain elsewhere, diminishing their overall ...

Of the phase III trials that planned to report QoL outcomes, nearly 40% never did ...

Please provide your email address to receive an email when new articles are posted on . Historically, patient-reported outcome measures were primarily used for research. Today, surgeons use ...

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Patient-reported outcome measures improve survival risk and quality of life for cancer patients, according to a study published Aug. 13 in JAMA Network Open. PROMs are self-reported statements from ...

Forbes contributors publish independent expert analyses and insights. Michael L. Millenson writes about healthcare as a skeptical optimist. An unusual study gives a new twist to the idea of ...

SAN DIEGO, June 2, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 4 KINECT-PROTM open-label study demonstrating robust and sustained ...

Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors. Among individuals with ...

An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last Each team from nine jurisdictions submitted a final report describing their PROM implementation project. Reports ...

April 10 meeting in Charlotte, NC, co-located with HMP Global’s SAWC Spring | WHS, advances regulatory science and ...